Mereo BioPharma Group Statistics

Total Valuation

LON:0A9G has a market cap or net worth of GBP 39.53 million. The enterprise value is 8.83 million.

Market Cap	39.53M
Enterprise Value	8.83M

Important Dates

The last earnings date was Thursday, March 26, 2026.

Earnings Date	Mar 26, 2026
Ex-Dividend Date	n/a

Share Statistics

Current Share Class	n/a
Shares Outstanding	n/a
Shares Change (YoY)	+7.77%
Shares Change (QoQ)	+0.06%
Owned by Insiders (%)	n/a
Owned by Institutions (%)	n/a
Float	114.47M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	106.40
PB Ratio	1.30
P/TBV Ratio	1.32
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

EV / Earnings	-0.28
EV / Sales	23.48
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	-0.38

Financial Position

The company has a current ratio of 10.46, with a Debt / Equity ratio of 0.00.

Current Ratio	10.46
Quick Ratio	9.99
Debt / Equity	0.00
Debt / EBITDA	n/a
Debt / FCF	-0.01
Interest Coverage	-151.20

Financial Efficiency

Return on equity (ROE) is -82.21% and return on invested capital (ROIC) is -44.41%.

Return on Equity (ROE)	-82.21%
Return on Assets (ROA)	-39.41%
Return on Invested Capital (ROIC)	-44.41%
Return on Capital Employed (ROCE)	-92.65%
Weighted Average Cost of Capital (WACC)	6.40%
Revenue Per Employee	9,526
Profits Per Employee	-797,830
Employee Count	39
Asset Turnover	0.01
Inventory Turnover	n/a

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -85.74% in the last 52 weeks. The beta is 0.33, so LON:0A9G's price volatility has been lower than the market average.

Beta (5Y)	0.33
52-Week Price Change	-85.74%
50-Day Moving Average	0.42
200-Day Moving Average	1.52
Relative Strength Index (RSI)	32.77
Average Volume (20 Days)	80,546

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	0.77

Income Statement

In the last 12 months, LON:0A9G had revenue of GBP 371,500 and -31.12 million in losses. Loss per share was -0.20.

Revenue	371,500
Gross Profit	272,681
Operating Income	-28.65M
Pretax Income	-31.12M
Net Income	-31.12M
EBITDA	-28.19M
EBIT	-28.65M
Loss Per Share	-0.20

Full Income Statement

Balance Sheet

The company has 30.46 million in cash and 150,086 in debt, with a net cash position of 30.31 million.

Cash & Cash Equivalents	30.46M
Total Debt	150,086
Net Cash	30.31M
Net Cash Per Share	n/a
Equity (Book Value)	30.40M
Book Value Per Share	0.19
Working Capital	30.25M

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -23.01 million and capital expenditures -14,860, giving a free cash flow of -23.03 million.

Operating Cash Flow	-23.01M
Capital Expenditures	-14,860
Depreciation & Amortization	468,868
Net Borrowing	n/a
Free Cash Flow	-23.03M
FCF Per Share	n/a

Full Cash Flow Statement

Margins

Gross Margin	73.40%
Operating Margin	-7,711.40%
Pretax Margin	-8,375.60%
Profit Margin	n/a
EBITDA Margin	n/a
EBIT Margin	n/a
FCF Margin	n/a

Dividends & Yields

LON:0A9G does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-7.77%
Shareholder Yield	-7.77%
Earnings Yield	-78.72%
FCF Yield	-58.25%

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

LON:0A9G has an Altman Z-Score of 25.39 and a Piotroski F-Score of 2.

Altman Z-Score	25.39
Piotroski F-Score	2